Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.
Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.
Transcript:
How have patients reacted to being prescribed [calcitonin gene-related peptide] CGRP inhibitors?
In contrast to what we believed, patients are calling and rushing into the office to get the CGRP drugs because they're safe, they're effective, [they have] minimal if any side effects, and they don't have to take a pill every day.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More